Table 1.
Selected baseline characteristics of three groups: Subjects who had hysterectomy during study follow-up (HDF); those who had hysterectomy before enrollment (HBE); and women enrolled in the Women's Interagency HIV Study (WIHS) who never had a hysterectomy (No Hys).
| Characteristic at baseline | No Hys^ | HDF | p-value* No Hys vs HDF | HBE | p-value* HDF vs HBE |
|---|---|---|---|---|---|
| Sample Size | N=2294 | N=103 | N=219 | ||
| Median age (IQR) in years | 35 (30-40) | 38 (33-41) | 0.005 | 45 (41-50) | <0.0001 |
| Race and Ethnicity: N (%) | 0.55 | 0.03 | |||
| White Non-Hispanic | 417 (18%) | 13 (13%) | 32 (15%) | ||
| Black Non-Hispanic | 1225 (53%) | 60 (58%) | 154 (70%) | ||
| Hispanic | 652 (28%) | 30 (29%) | 33 (15%) | ||
| Income at baseline: N (%) | 0.07 | 0.26 | |||
| < $18,000 | 1656 (76%) | 69 (68%) | 162 (76%) | ||
| $18,001 - $36,000 | 372 (17%) | 26 (26%) | 38 (18%) | ||
| ≥ $36,001 | 165 ( 8%) | 6 ( 6%) | 12 (6%) | ||
| Smoking at baseline: N (%) | 0.91 | 0.002 | |||
| Never | 631 (28%) | 28 (27%) | 28 (13%) | ||
| Former | 353 (15%) | 17 (17%) | 53 (24%) | ||
| Current | 1300 (57%) | 58 (56%) | 138 (63%) | ||
| Oral contraceptive use at baseline: N (%) | 0.42 | 0.01 | |||
| Never | 670 (29%) | 26 (25%) | 67 (31%) | ||
| Former | 1488 (65%) | 73 (71%) | 151 (69%) | ||
| Current | 133 (6%) | 4 ( 4%) | 0 ( 0%) | ||
| HIV-status: N (%) | 0.18 | 0.76 | |||
| HIV-negative | 502 (22%) | 17 (16%) | 33 (15%) | ||
| HIV-positive | 1778 (78%) | 86 (84%) | 184 (85%) | ||
| Median CD4+ T-cell count among HIV-seropositive (IQR) | 332 (157-519) | 333 (230-513) | 0.29 | 296 (175-465) | 0.09 |
| Number of sexual partners during 6 months prior to baseline: N (%) | 0.20 | 0.53 | |||
| 0 | 703 (31%) | 37 (36%) | 99 (46%) | ||
| 1(married) | 370 (16%) | 23 (22%) | 41 (19%) | ||
| 1(single) | 815 (36%) | 30 (29%) | 50 (23%) | ||
| 2 | 209 (9%) | 9 (9%) | 17 (8%) | ||
| ≥ 3 | 171 (8%) | 4 (4%) | 10 (5%) | ||
| LSIL+ at baseline: N (%) | 0.006 | NA | |||
| No | 1946 (85%) | 77 (75%) | |||
| Yes | 348 (15%) | 26 (25%) | NA | ||
| Cervicovaginal HPV prevalence at baseline: N (%) | |||||
| Any HPV | 986 (48%) | 53 (57%) | 0.10 | 107 (55%) | 0.81 |
| Any oncogenic HPV | 509 (25%) | 33 (35%) | 0.02 | 39 (20%) | 0.005 |
| Any non-oncogenic HPV | 778 (38%) | 36 (39%) | 0.91 | 92 (48%) | 0.15 |
Additional abbreviations: LSIL=low grade squamous intraepithelial lesion.
*
chi-square for categorical or test of medians for continuous data
^
Although women who never have a hysterectomy were not subjects in the current substudy they were included in this table to allow readers to compare the characteristics of women who were subjects to those of the larger WIHS cohort.